RHS Financial LLC Invests $695,000 in Exelixis, Inc. $EXEL

RHS Financial LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, Holdings Channel reports. The institutional investor bought 12,779 shares of the biotechnology company’s stock, valued at approximately $695,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. Motiv8 Investments LLC acquired a new stake in Exelixis during the 4th quarter worth $26,000. Cassaday & Co Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at $27,000. Western Wealth Management LLC acquired a new position in Exelixis in the first quarter valued at $29,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Exelixis in the fourth quarter valued at about $29,000. Finally, Activest Wealth Management purchased a new stake in shares of Exelixis in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 1.5%

Shares of NASDAQ:EXEL opened at $53.12 on Wednesday. The company has a market cap of $13.16 billion, a P/E ratio of 16.70, a PEG ratio of 1.53 and a beta of 0.44. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $57.57. The company has a 50-day moving average price of $54.20 and a 200 day moving average price of $48.35.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. Analysts expect that Exelixis, Inc. will post 3.18 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Stifel Nicolaus upped their price objective on Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $56.00 target price on shares of Exelixis in a research note on Thursday, July 2nd. TD Cowen boosted their target price on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings raised Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $50.07.

Insiders Place Their Bets

In related news, Director Sue Gail Eckhardt sold 9,812 shares of Exelixis stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $50.14, for a total value of $491,973.68. Following the sale, the director directly owned 16,079 shares in the company, valued at $806,201.06. The trade was a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack L. Wyszomierski sold 3,925 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.55, for a total value of $198,408.75. Following the transaction, the director directly owned 284,384 shares in the company, valued at $14,375,611.20. This represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock valued at $3,404,652 over the last 90 days. 2.60% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.